These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
171 related items for PubMed ID: 9816271
21. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Kim DH, Kim JS, Park JH, Lee SK, Ji YI, Kwon YM, Shim YM, Han J, Park J. Cancer Res; 2003 Oct 01; 63(19):6206-11. PubMed ID: 14559805 [Abstract] [Full Text] [Related]
22. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E. Cancer Res; 1999 Nov 01; 59(21):5572-7. PubMed ID: 10554037 [Abstract] [Full Text] [Related]
23. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing. Chong IW, Chang MY, Sheu CC, Wang CY, Hwang JJ, Huang MS, Lin SR. Oncol Rep; 2007 Jul 01; 18(1):17-24. PubMed ID: 17549340 [Abstract] [Full Text] [Related]
24. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application]. Zhang G, Sun Y, Wang M. Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct 01; 18(5):282-4, 317. PubMed ID: 8762479 [Abstract] [Full Text] [Related]
25. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, Kelsey KT. Oncogene; 2001 Mar 29; 20(14):1765-70. PubMed ID: 11313923 [Abstract] [Full Text] [Related]
26. K-ras genotypes and prognosis in non-small-cell lung cancer. Rosell R, Monzo M, Molina F, Martinez E, Pifarre A, Moreno I, Mate JL, de Anta JM, Sanchez M, Font A. Ann Oncol; 1995 Mar 29; 6 Suppl 3():S15-20. PubMed ID: 8616107 [Abstract] [Full Text] [Related]
27. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ, Doroshow JH, Lenz HJ, Gandara DR, Gumerlock PH. Ann N Y Acad Sci; 2004 Jun 29; 1022():55-60. PubMed ID: 15251940 [Abstract] [Full Text] [Related]
29. [Significance of heterozygosity loss in the long arm of chromosome 5 (5q21) in small cell carcinoma of the lung]. Sánchez Céspedes M, López Cabrerizo MP, Moreno I, Ariza A, Monzó M, Rosell R. Med Clin (Barc); 1997 May 31; 109(1):1-5. PubMed ID: 9303970 [Abstract] [Full Text] [Related]
30. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Hu Y, McDermott MP, Ahrendt SA. Clin Cancer Res; 2005 Apr 01; 11(7):2502-9. PubMed ID: 15814626 [Abstract] [Full Text] [Related]
31. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A. Clin Cancer Res; 2000 Mar 01; 6(3):1031-7. PubMed ID: 10741731 [Abstract] [Full Text] [Related]
32. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer. Sekine I, Takami S, Guang SG, Yokose T, Kodama T, Nishiwaki Y, Kinoshita M, Matsumoto H, Ogura T, Nagai K. Oncol Rep; 1998 Mar 01; 5(2):351-4. PubMed ID: 9468555 [Abstract] [Full Text] [Related]
33. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabrò MG, De Pas T, Orlando L, Mandalà M, Colleoni M, Spaggiari L, Granone PL, Pagliari G, de Braud F, Fazio N, Goldhirsch A. Clin Cancer Res; 2000 Jun 01; 6(6):2393-400. PubMed ID: 10873091 [Abstract] [Full Text] [Related]
34. K-ras activation in non-small cell lung cancer in the dog. Kraegel SA, Gumerlock PH, Dungworth DL, Oreffo VI, Madewell BR. Cancer Res; 1992 Sep 01; 52(17):4724-7. PubMed ID: 1324792 [Abstract] [Full Text] [Related]
35. High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Scott FM, Modali R, Lehman TA, Seddon M, Kelly K, Dempsey EC, Wilson V, Tockman MS, Mulshine JL. Clin Cancer Res; 1997 Mar 01; 3(3):479-82. PubMed ID: 9815708 [Abstract] [Full Text] [Related]
36. k-ras mutation and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis. Nelson HH, Christiani DC, Wiencke JK, Mark EJ, Wain JC, Kelsey KT. Cancer Res; 1999 Sep 15; 59(18):4570-3. PubMed ID: 10493509 [Abstract] [Full Text] [Related]
39. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H. Oncogene; 1990 Oct 15; 5(10):1603-10. PubMed ID: 1979160 [Abstract] [Full Text] [Related]
40. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study. Fernando HC, Sasatomi E, Christie NA, Buenaventura PO, Finkelstein SD, Yousem SA, Soose R, Close JM, Luketich JD. J Thorac Cardiovasc Surg; 2004 Jan 15; 127(1):87-91. PubMed ID: 14752417 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]